Fengwei Tan
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Lung Cancer Diagnosis and Treatment 27
- Lung Cancer Treatments and Mutations 16
- Ferroptosis and cancer prognosis 10
-
- RNA modifications and cancer 19
- Co-authors
- Jie He (60 shared papers)Qi Xue (61 shared papers)Yibo Gao (21 shared papers)Wei Guo (23 shared papers)Shugeng Gao (30 shared papers)Shugeng Gao (36 shared papers)Bin Qiu (15 shared papers)Xiaogang Tan (7 shared papers)
- Journals
- Translational Lung Cancer Research (9 papers)Frontiers in Oncology (5 papers)Cancer Medicine (4 papers)Annals of Translational Medicine (4 papers)Frontiers in Immunology (4 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Fengwei Tan
119 papers receiving 2.7k citations
Fengwei Tan's Hit Papers
Peers
Comparison fields: 5 of 106
- Cancer Research 874
- Oncology 644
- Pulmonary and Respiratory Medicine 638
- Molecular Biology 1.0k
- Immunology 191
Countries citing papers authored by Fengwei Tan
This map shows the geographic impact of Fengwei Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengwei Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengwei Tan more than expected).
Fields of papers citing papers by Fengwei Tan
This network shows the impact of papers produced by Fengwei Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengwei Tan. The network helps show where Fengwei Tan may publish in the future.
Co-authors
The 25 scholars most cited alongside Fengwei Tan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 121 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis Hit paper breakdown → | 2021 | 177 |
| 2 | 2021 | 162 | |
| 3 | 2018 | 142 | |
| 4 | 2010 | 132 | |
| 5 | 2011 | 112 | |
| 6 | 2012 | 103 | |
| 7 | 2020 | 92 | |
| 8 | 2013 | 92 | |
| 9 | 2011 | 86 | |
| 10 | 2019 | 71 | |
| 11 | 2021 | 71 | |
| 12 | 2019 | 68 | |
| 13 | 2022 | 52 | |
| 14 | 2022 | 47 | |
| 15 | 2020 | 45 | |
| 16 | 2014 | 43 | |
| 17 | 2021 | 41 | |
| 18 | 2022 | 40 | |
| 19 | 2023 | 39 | |
| 20 | 2022 | 35 |
About Fengwei Tan
Fengwei Tan is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, Oncology and Surgery, having authored 121 papers that have together received 2.8k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (27 papers), RNA modifications and cancer (19 papers), Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (13 papers), Cancer-related molecular mechanisms research (12 papers), Ferroptosis and cancer prognosis (10 papers), MicroRNA in disease regulation (10 papers) and Lung Cancer Research Studies (7 papers). The work is most often cited by research in Cancer Research (874 citations), Oncology (644 citations), Pulmonary and Respiratory Medicine (638 citations), Molecular Biology (1.0k citations) and Immunology (191 citations). Fengwei Tan has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Jie He, Qi Xue, Yibo Gao, Wei Guo, Shugeng Gao, Shugeng Gao, Bin Qiu, Xiaogang Tan, Zhaoli Chen and Guochao Zhang. Their work appears in journals such as Translational Lung Cancer Research, Frontiers in Oncology, Cancer Medicine, Annals of Translational Medicine and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.